Close Menu

NEW YORK – The US Centers for Medicare and Medicaid Services has finalized the draft national coverage decision memo it issued last October, describing criteria for the coverage of blood-based colorectal cancer screening tests, but denying coverage for Epigenomics' Epi ProColon assay.

Apart from Epigenomics, the memo stands to impact a number of companies developing genomic and epigenomic blood tests for colorectal cancer including Guardant Health, Freenome, Exact Sciences, and others.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

In a letter, about two dozen researchers criticize the World Health Organization investigation into the origins of SARS-CoV-2 and call for a new inquiry, the Wall Street Journal reports.

National Geographic reports that nine great apes at the San Diego Zoo have been vaccinated against SARS-CoV-2.

Janet Woodcock, the acting commissioner of the US Food and Drug Administration, speaks with NPR about SARS-CoV-2 testing and vaccines in the US.

In Science this week: genetic study of kidney fibrosis implicates the SOX9-NAV3-YAP1 axis.